Revenue Breakdown
Composition ()
No data
Revenue Streams
Qiagen NV (QGEN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables and Related Revenues, accounting for 90.4% of total sales, equivalent to $481.20M. Another important revenue stream is Instrumentation. Understanding this composition is critical for investors evaluating how QGEN navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Qiagen NV maintains a gross margin of 59.77%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 22.55%, while the net margin is 19.95%. These profitability ratios, combined with a Return on Equity (ROE) of 11.57%, provide a clear picture of how effectively QGEN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, QGEN competes directly with industry leaders such as BAX and RVTY. With a market capitalization of $9.85B, it holds a significant position in the sector. When comparing efficiency, QGEN's gross margin of 59.77% stands against BAX's 20.24% and RVTY's 54.62%. Such benchmarking helps identify whether Qiagen NV is trading at a premium or discount relative to its financial performance.
